KCNQ5-AS1: A Potential Drug Target and Biomarker (G100873997)

Target Name: KCNQ5-AS1

NCBI ID: G100873997

KCNQ5-AS1

Other Name(s): KCNQ5 antisense RNA 1 (non-protein coding) | KCNQ5 antisense RNA 1

KCNQ5-AS1: A Potential Drug Target and Biomarker

K can downregulate the activity of AS1, a protein that plays a critical role in the regulation of ion channels and neurotransmitter release in the brain. As a result, individuals with AS1 mutations, such as those withKCNQ5-AS1 syndrome, experience increased neuronal excitability, leading to a range of symptoms including muscle rigidity, hyperthermia, and aggressive behavior. While there are currently no approved drugs to treat AS1 mutations, new research has identified a potential drug target in the protein KCNQ5-AS1 and its associated symptoms.

The protein KCNQ5-AS1 is a member of the subfamily of channel-type potassium channels, known as the N-type channel. These channels are involved in the regulation of neuronal excitability and play a crucial role in the transmission of electrical signals in the brain. The AS1 gene, which encodes the protein AS1, has been implicated in the regulation of neuronal excitability and is a target for several neurotransmitters, including GABA, which is known for its inhibitory effects on neurons.

Studies have shown that individuals with AS1 mutations have increased activity of the AS1 protein and increased neuronal excitability. This increased activity is thought to contribute to the symptoms of AS1 mutations, including muscle rigidity, hyperthermia, and aggressive behavior. While these symptoms can be distressing, they are not typically life-threatening.

The potential drug target in KCNQ5-AS1 is its associated with the regulation of neuronal excitability and the transmission of electrical signals in the brain. By targeting this protein and its associated symptoms, researchers hope to develop new treatments for individuals with AS1 mutations. This could lead to a better quality of life for individuals with these conditions and provide new hope for those seeking treatment.

In conclusion, KCNQ5-AS1 is a potential drug target and biomarker for the treatment of AS1 mutations. Further research is needed to understand the full effects of targeting this protein and its associated symptoms. However, the potential for new treatments is a promising development in the field of neurodegenerative diseases.

Protein Name: KCNQ5 Antisense RNA 1

The "KCNQ5-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNQ5-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets